Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.67M Sell
6,323
-25
-0.4% -$10K 1.18% 25
2026
Q2
$2.3M Buy
6,348
+72
+1% +$24.6K 1.03% 31
2026
Q1
$2.21M Sell
6,276
-65
-1% -$23.2K 1.13% 28
2025
Q4
$2.08M Sell
6,341
-203
-3% -$64.4K 1.01% 28
2025
Q3
$1.85M Buy
6,544
+18
+0.3% +$5.22K 0.9% 31
2025
Q2
$1.82M Hold
6,526
– – 0.97% 28
2025
Q1
$2.03M Buy
6,526
+5
+0.1% +$1.48K 1.21% 21
2024
Q4
$1.7M Sell
6,521
-7
-0.1% -$2.08K 1.07% 26
2024
Q3
$2.1M Buy
6,528
+103
+2% +$33.7K 1.38% 18
2024
Q2
$2.01M Buy
6,425
+80
+1% +$23.5K 1.48% 18
2024
Q1
$1.8M Sell
6,345
-88
-1% -$25.8K 1.39% 22
2023
Q4
$1.85M Buy
+6,433
New +$1.75M 1.51% 17

Other funds holding AMGN

Wynn Capital's AMGN Position: Q3 2026 in Review

Wynn Capital reduced its Amgen (AMGN) stake by 0.39% in Q3 2026, selling an estimated $10K and leaving 6,323 shares worth $2.67M. The position accounts for 1.18% of the portfolio, ranked #25.

Wynn Capital first reported a position in AMGN in Q4 2023 and has held it in 12 quarters since. 3,271 funds tracked by Wall St. Rank hold AMGN as of Q3 2026.

  • Wynn Capital held 6,323 shares of Amgen worth $2.67M as of Q3 2026.
  • Wynn Capital sold 25 Amgen shares in Q3 2026, an estimated $10K.
  • Amgen made up 1.18% of Wynn Capital's portfolio in Q3 2026, its #25 holding.
  • Wynn Capital first reported a position in Amgen in Q4 2023 and has held it in 12 quarters since.
  • 3,271 funds tracked by Wall St. Rank held Amgen as of Q3 2026.

Based on Wynn Capital's 13F filing for Q3 2026, filed 13 Oct 2026.